Everolimus and the Recurrence of Hepatocellular Carcinoma after liver transplantation: A Nationwide Emulated Target Trial Based on Real-World Data

Authors:

Abstract
Background: Hepatocellular carcinoma (HCC) is a major indication for liver transplantation (LT). Post-transplant recurrence affects approximately 15% of patients. Everolimus (EVR), an mTOR inhibitor, can reduce recurrence through antitumor effects; however, supporting data remain heterogeneous. Objective: To evaluate the association between EVR use and HCC recurrence following LT for HCC. Methods: Emulated target trials were conducted using French nationwide administrative health data. The cloning–censoring–weighting approach was applied to estimate the effects of EVR initiation and discontinuation after initiation. The primary outcome was the cumulative incidence of HCC recurrence. The secondary outcome was overall survival. Results: Between 2009 and 2020, 3,670 patients underwent LT for HCC, 958 of whom (26.1%) initiated everolimus within three years of LT. The 5-year HCC recurrence rate was 12.5%. Everolimus initiation within three years of LT was associated with lower HCC recurrence at 5 years (HR 0.75; 95% CI 0.64–0.91) and 10 years (HR 0.77; 95% CI 0.61–0.95) and improved 5-year survival (HR 0.92; 95% CI 0.88–0.94). Among everolimus users, discontinuation increased the HCC recurrence risk at 5 years (HR 1.83; 95% CI 1.77–1.93) and 10 years (HR 1.51; 95% CI 1.29–1.71), with reduced survival at both time points (5 years: HR 1.63; 95% CI 1.55–1.87; 10 years: HR 1.63; 95% CI 1.55–1.87). Everolimus initiation 1 year pre-recurrence improved post-recurrence survival (HR 0.64; 95% CI 0.47–0.87; p = 0.005). Conclusion: Everolimus use after LT for HCC reduces the risk of recurrence and improves survival. Discontinuation increases the risks of recurrence and mortality. These findings support the use of everolimus as a key component of immunosuppression in HCC transplant patients, emphasizing the importance of treatment continuity.